Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus‐endemic population
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Most mortalities from liver disease and liver cancer worldwide are attributable to hepatitis B virus (HBV) and hepatitis C virus. Despite remarkable advances in the treatment of HBV over past decades, limited population‐level data are available regarding its impact on burden of liver disease and liver cancer. Mortality data from liver disease and liver cancer were obtained from the national death certificate database of Korea, an HBV‐endemic country, between 1999 and 2013, and were analyzed by Joinpoint analysis. For liver disease, number of annual deaths decreased by 62.3% (95% confidence interval [CI], 62.0‐62.6), crude death rate (CDR) decreased by 64.6% (95% CI, 64.3‐64.9) from 21.2 to 7.5 per 100,000 population, and age‐standardized death rate (ADR) declined by 75.0% (95% CI, 74.7‐75.3), between 1999 and 2013. In contrast, for liver cancer, number of annual deaths increased by 17.8% (95% CI, 17.6‐18.0) and CDR increased by 10.2% (95% CI, 10.0‐10.4) from 20.5 to 22.6, although ADR decreased by 26.9% (95% CI, 26.6‐27.2). The annual number of patients receiving oral antiviral agents against HBV increased from 1,716 to 187,226 during the study period. The increase in mean age at death from liver disease was significantly greater than that from liver cancer (8.8 vs. 6.1 years: P = 0.02). Conclusion: Marked reduction in liver disease mortality by widespread use of antiviral treatments against HBV may increase the life expectancy and number of patients at risk of developing liver cancer, inadvertently leading to increased burden of liver cancer in an HBV‐endemic population. The competing nature between death from liver disease and that from liver cancer should be carefully considered in establishing a health care policy. (H epatology 2017;66:1454–1463).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Self-citationEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis
Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014) · BMC Medicine · doi:10.1186/s12916-014-0145-y · Cited by 1,129 · cited 3×
“Based on the global burden of disease (GBD) 2010 Gastrointestinal Diseases expert group recommendations,((11)) we obtained the annual number of deaths from liver disease, including VH (ICD-10 codes K71-K79 and B15-19) and liver cancer (ICD-10 code C22) for analysis.”
MethodResultKeyes, K. M., Utz, R. L., Robinson, W., & Li, G. (2010) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.12.018 · Cited by 292 · cited 1×
“To elucidate differences in mortalities from liver disease and liver cancer by birth cohort, we analyzed agespecific mortality (ASM) by various birth cohorts consisting of age groups with 5-year intervals (starting from 20 to 24 to >85 years) and birth cohorts with 5year intervals (starting from 1910-1914 to 19901995)…”
Method
Cited by
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
International trends in hepatocellular carcinoma incidence, 1978–2012
Petrick, J. L., Florio, A. A., Znaor, A., Ruggieri, D., Laversanne, M., Alvarez, C. S., Ferlay, J., Valery, P. C., Bray, F., & McGlynn, K. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32723 · Cited by 594
“This led the authors to speculate that nucleos(t)ide analog therapy may increase the opportunity to develop HCC, because individuals with HBV infection are living longer.(29) The decreasing rates of HCC in Japan and Italy are likely due to a decline in HCV prevalence in these populations.”
BackgroundInfluentialKorean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
The changing epidemiology of liver diseases in the Asia–Pacific region
Wong, M. C. S., Huang, J. L. W., George, J., Huang, J., Leung, C., Eslam, M., Chan, H. L. Y., & Ng, S. C. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0055-0 · Cited by 344
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Epidemiology of liver cancer in South Korea
Kim, B. H., & Park, J.-W. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0112 · Cited by 189
“A recent study suggested that widespread use of antiviral agents for HBV might increase the number of patients at risk of developing liver cancer as well as the individual’s life expectancy while decreasing the mortality from underlying liver disease.(14) Based on the mortality data from the Korean Statistical Informa…”
BackgroundInfluentialThe Changing Epidemiology of Primary Liver Cancer
Petrick, J. L., & McGlynn, K. A. (2019) · Current Epidemiology Reports · doi:10.1007/s40471-019-00188-3 · Cited by 170
Kim, H., An, J., Park, J., Park, S., Lim, Y., & Lee, E. (2019) · Hepatology · doi:10.1002/hep.30330 · Cited by 114
“HCC has been the fastest-rising cause of cancer-related deaths in Western countries over the past two decades, and its incidence is expected to increase further in the coming decades.(2,3) Most mortalities from HCC are”
BackgroundSelf-citationReveron‐Thornton, R. F., Teng, M. L. P., Lee, E. Y., Tran, A., Vajanaphanich, S., Tan, E. X., Nerurkar, S. N., Ng, R. X., Teh, R., Tripathy, D. P., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1923 · Cited by 97
Metadata
- Authors
- Choi, J., Han, S., Kim, N., & Lim, Y.
- Venue
- Hepatology
- Published
- 2017-10-11
- Volume
- 66
- Issue
- 5
- Pages
- 1454-1463
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2639316115
- Cited by
- 108
- References
- 5
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.